DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Contactexpress Faqs Legends Search Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | AliX | Alizé Pharma | Alphelys | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Atlantic Bone Screen | Aureus Pharma | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | BioMedical Diagnostics | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-modeling) | BT Pharma | Carmat | Cellectis | Cellial Technologies | CellVax | CellVir | Cerenis Therapeutics | Cezanne | CliniGenetics | Covalab | Cytheris | Cytomics | Cytoo | DBV Technologies | DNA Therapeutics | Domain Therapeutics | Dynabio | EchoSens | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Exonhit | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | GenOdyssee | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | GTP Technology | Helios Biosciences | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences (AbAg) | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | LibraGen | Magnisense | Mapreg | MAT Biopharma | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MicroBioChips | MilleGen | MitoProd | Murigenetics | Mutabilis | Myosix | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NicOx | Nokad | Nosopharm | Nova Decision | Novagali | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharmaxon | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | PraXcell | Proteogenix | Protéus | Protexel | PX’Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sepal Pharma | Serial Genetics | Sisène Biotechnologies | Skuld-Tech | Synapcell | Synprosis | Tc Land Expression | Theraclion | TheraVectys | Transgene | Trophos | TxCell | UroGene | UROsphere | Urrma | Vaxon Biotech | Vectalys | VigiCell | Vivalis | XenTech | Zeta Biotech |

* IMMUTEP *

2001 - IDF
Orsay
(near Paris)
www.immutep.com

Discovery, Immunology
(also, Discovery, Diagnostics)
Key words: Cancer, Chronic Infectious Diseases, T Cell Immune responses, Immuno-therapy, MABs, Vaccines, Lag-3 protein
Mission: to develop immunostimulatory factors for the treatment of cancer and chronic infectious diseases and immunomodulatory therapeutic antibodies for the treatment of cancers or autoimmune diseases
Clients: Prescribers
admin@immutep.com

Age: 8 year(s)

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Hawken (John B.) [co-founder, born 1948, Ms. chemistry (Oxford), MBA, ex-Diatos, EntoMed, Neurotech, Aptanomics, Shell]
Sc.Dir.-CSO: Triebel (Frédéric) [co-founder, born 1954, M.D., Ph.D. immunology, ex-Inserm, Prof. Immunology, Paris University, Institut Gustave Roussy (IGR)]
Fin.Dir.-CFO:
BusDev:
Financers (Hist.): Innoven Partenaires, H2I

Turnover (M€) : 0.009 (2008), 0.009 (2006)
Total funding (M€) : 6.7
Last funding (M€) : 2.5
Focus : Cancers
Position : Clinical
Company confirm : none

History
DATEMILESTONETYPETIME
2009 .01 Clinical trial (phase II interim) for ImmuFact IMP321 associated with paclitaxel doubles clinical response rate in Metastatic Breast Cancer (confirmed in January 2010, with final results) CLIN [7 years]
2008 .10 Registration : FDA IND allowance for IMP321 in Pancreatic Cancer MKTG [7 years]
2005 .04 Clinical trial (phase II) for IMP321 (beginning) CLIN [3 years]
2005 .01 2nd round-financing : 2.5 M€, by Innoven, for the lead compound IMP321 (immuno-stimulation factor) RFINB [3 years]
2003 .12 1st round-financing : 2.5 M€, by FCPI La Poste Innovation, Innoven RFINA [2 years]
2001 .09 Company founded by Prof. Frédéric Triebel and John B. Hawken, as a spin-off from Institut Gustave Roussy (the largest cancer center clinic in Europe, located South of Paris) and Serono (today Merck-Serono) ORGF [0 year]

Actualisation / Updating: 04-Janv-2010

Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT
Pour retourner à la page d'accueil Biotech: BIENVENUE !

Haut de page :

Copyright J.H. Huber, Pharmaclient 2001-2010.

Pharmaclient, le site de la valorisation client en Pharma, est la vitrine des activités de conseil de Jean Huber: Stratégie, Communication, Relation Client en Pharma.